Intercept Pharmaceuticals, Inc.
INTERCEPT PHARMACEUTICALS INC (Form: SC 13G/A, Received: 11/09/2017 16:48:22)

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Amendment #3

Under the Securities and Exchange Act of 1934

 

 

Intercept Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

45845P108

(CUSIP Number)

October 31, 2017

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

This Schedule is filed pursuant to Rule 13d-1(b)

The information required in the remainder of this cover page (except any items to which the form provides a cross-reference) shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

 

 

 


CUSIP NO. 45845P108  

 

  1)   

Name of Reporting Person

S.S. or I.R.S. Identification No. of Above Person

 

Ameriprise Financial, Inc.

IRS No. 13-3180631

  2)  

Check the Appropriate Box if a Member of a Group

(a)  ☐        (b)  ☒*

 

*  This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

  3)  

SEC Use Only

 

  4)  

Citizenship or Place of Organization

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

   5)    

Sole Voting Power

 

0

   6)   

Shared Voting Power

 

891,970

   7)   

Sole Dispositive Power

 

0

   8)   

Shared Dispositive Power

 

1,185,405

  9)  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,185,405

10)  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11)  

Percent of Class Represented by Amount In Row (9)

 

4.72%

12)  

Type of Reporting Person

 

HC


CUSIP NO. 45845P108  

 

  1)   

Name of Reporting Person

S.S. or I.R.S. Identification No. of Above Person

 

Columbia Management Investment Advisers, LLC

IRS No. 41-1533211

  2)  

Check the Appropriate Box if a Member of a Group

(a)  ☐        (b)  ☒*

 

*  This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

  3)  

SEC Use Only

 

  4)  

Citizenship or Place of Organization

 

Minnesota

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

   5)    

Sole Voting Power

 

0

   6)   

Shared Voting Power

 

891,970

   7)   

Sole Dispositive Power

 

0

   8)   

Shared Dispositive Power

 

1,185,405

  9)  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,185,405

10)  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11)  

Percent of Class Represented by Amount In Row (9)

 

4.72%

12)  

Type of Reporting Person

 

IA


1(a)   Name of Issuer:    Intercept Pharmaceuticals, Inc.
1(b)   Address of Issuer’s Principal Executive Offices:   

450 W. 15th Street, Suite 505

New York, NY 10011

2(a)   Name of Person Filing:    (a) Ameriprise Financial, Inc. (“AFI”)
    

(b) Columbia Management Investment

Advisers, LLC (“CMIA”)

2(b)   Address of Principal Business Office:   

(a) Ameriprise Financial, Inc.

145 Ameriprise Financial Center

     Minneapolis, MN 55474
     (b) 225 Franklin St.
     Boston, MA 02110
    
2(c)   Citizenship:   

(a) Delaware

(b) Minnesota

2(d)   Title of Class of Securities:    Common Stock
2(e)   Cusip Number:    45845P108

 

3 Information if statement is filed pursuant to Rules 13d-1(b) or 13d-2(b):

(a) Ameriprise Financial, Inc.

A parent holding company in accordance with Rule 13d-1(b)(1)(ii)(G). (Note: See Item 7)

(b) Columbia Management Investment Advisers, LLC

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

 

4 Incorporated by reference to Items (5)-(9) and (11) of the cover page pertaining to each reporting person.

AFI, as the parent company of CMIA, may be deemed to beneficially own the shares reported herein by CMIA. Accordingly, the shares reported herein by AFI include those shares separately reported herein by CMIA.

Each of AFI and CMIA disclaims beneficial ownership of any shares reported on this Schedule.

 

5 Ownership of 5% or Less of a Class:

If this statement is being filed to report the fact as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X).


6 Ownership of more than 5% on Behalf of Another Person: Not Applicable

 

7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

AFI: See Exhibit I

 

8 Identification and Classification of Members of the Group:

Not Applicable

 

9 Notice of Dissolution of Group:

Not Applicable

 

10 Certification:

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.


Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 9, 2017

 

Ameriprise Financial, Inc.
By:  

Amy K. Johnson

  Name: Amy K. Johnson
  Title: Senior Vice President and Chief Operating Officer-Asset Management
Columbia Management Investment Advisers, LLC
By:  

Amy K. Johnson

  Name: Amy K. Johnson
  Title: Managing Director and Global Head of Operations

Contact Information

  Mark D. Braley
  Vice President
  Head of Reporting and Data Management | Global Operations and Investor Services
  Telephone: (617) 747-0663


Exhibit Index

 

Exhibit I

  Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

Exhibit II

  Joint Filing Agreement

 

Exhibit I

to

Schedule 13G

Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows:

Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

 

Exhibit II

to

Schedule 13G

Joint Filing Agreement

The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated November 9, 2017 in connection with their beneficial ownership of Intercept Pharmaceuticals, Inc.. Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the Schedule 13G to which this Exhibit is attached and make any necessary amendments thereto.

 

Ameriprise Financial, Inc.
By:  

/s/ Amy K. Johnson

  Amy K. Johnson
  Title: Senior Vice President and
            Chief Operating Officer-Asset Management
Columbia Management Investment Advisers, LLC
By:  

/s/ Amy K. Johnson

  Amy K. Johnson
  Title: Managing Director and Global Head of Operations